Dr. Brentjens is a medical oncologist specializing in the treatment of acute and chronic leukemias. He obtained his medical degree and Ph.D. (microbiology) at the State University of New York at Buffalo, and completed his residency in medicine at Yale New Haven Hospital and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and is an attending physician on the leukemia service.
His ongoing pre-clinical and clinical research is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells.”
